Be sure to check our sister interview main ratings news website

Poolbeg Pharma’s SAB endorses influenza drug targets identified in AI-led drug discovery programme

Poolbeg Pharma plc (LON:POLB) a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, has announced that its Scientific Advisory Board (‘SAB’) has endorsed the influenza drug targets identified in its AI-led drug discovery programme.

Key highlights

·      Prioritisation of influenza drug targets which have the highest likelihood of success

·      New potential collaborative routes to maximise the impact of the outputs identified

·      Ongoing discussions with prospective partners on these novel and exciting targets discovered using AI

The SAB was presented with comprehensive data and information regarding the large number of novel drug targets identified as part of the CytoReason collaboration in June 2023, along with a proposed list of prioritised candidates. Prioritisation was based on several key criteria and an evaluation by both Poolbeg and CytoReason’s teams of expert biologists and data scientists to identify the top-ranking genes potentially suitable for the treatment of influenza.

Read in Full
Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

AI-powered drug discovery is changing the future of medicine

31st January 2025

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

23rd January 2025

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

9th January 2025

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for

Poolbeg receives US patent for Immunomodulator development

21st November 2024

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

20th November 2024

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

14th November 2024

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.